Back
Kiniksa Pharmaceuticals Quote, Financials, Valuation and Earnings
Sponsored
KNSA
Sponsored
Biden's Oil War: The Administration Is All-In on Green Energy.
Download Free Report
Buy
75
KNSA
Kiniksa Pharmaceuticals
Last Price:
19.55
Seasonality Move:
18.68%
7 Day Trial
ALL ACCESS PASS
$
7
Billionaire Investors Join Forces to Fund Next Generation
Learn MoreKiniksa Pharmaceuticals Price Quote
$19.55
-0.44 (-2.2%)
(Updated: March 28, 2024 at 12:45 PM ET)
Kiniksa Pharmaceuticals Key Stats
Buy
75
Kiniksa Pharmaceuticals (KNSA)
is a Buy
Day range:
$19.88 - $20.16
52-week range:
$10.29 - $22.09
Dividend yield:
0%
P/E ratio:
99.95
P/S ratio:
5.35
P/B ratio:
3.22%
Volume:
330.1K
Avg. volume:
393.9K
1-year change:
75.97%
Market cap:
$1.4B
Revenue:
$270.3M
EPS:
$0.18
How Much Does Kiniksa Pharmaceuticals Make?
-
How Much Are Kiniksa Pharmaceuticals's Sales Annually?
KNSA Revenues are $270.3M -
How Much Profit Does Kiniksa Pharmaceuticals's Make A Year?
KNSA net income is $14.1M
Is Kiniksa Pharmaceuticals Growing As A Company?
-
What Is Kiniksa Pharmaceuticals's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.35% -
What Is Kiniksa Pharmaceuticals's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 4.83%
Kiniksa Pharmaceuticals Stock Price Performance
-
Did Kiniksa Pharmaceuticals Stock Go Up Last Month?
Kiniksa Pharmaceuticals share price went down by -4.31% last month -
Did KNSA's Share Price Rise Over The Last Year?
KNSA share price rose by 75.97% over the past 1 year
What Is Kiniksa Pharmaceuticals 52-Week High & Low?
-
What Is Kiniksa Pharmaceuticals’s 52-Week High Share Price?
Kiniksa Pharmaceuticals has traded as high as $22.09 over the past 52 weeks -
What Is Kiniksa Pharmaceuticals’s 52-Week Low Share Price?
Kiniksa Pharmaceuticals has traded as low as $10.29 over the past 52 weeks
Kiniksa Pharmaceuticals Price To Free Cash Flow
-
Is Kiniksa Pharmaceuticals Stock Overvalued?
Kiniksa Pharmaceuticals is trading at a price to free cash flow ratio of 109.81 -
Is Kiniksa Pharmaceuticals Stock Undervalued?
Kiniksa Pharmaceuticals EV to Free Cash Flow ratio is 91.51 -
What Is Kiniksa Pharmaceuticals’s Price Earnings Growth Ratio?
KNSA PEG ratio is 0.00 -
Is Kiniksa Pharmaceuticals Trading At A Premium To Earnings?
Kiniksa Pharmaceuticals EV to EBIT ratio is 0.00
Is It Risky To Buy Kiniksa Pharmaceuticals?
-
How Much Debt Does Kiniksa Pharmaceuticals Have?
Total long term debt quarterly is $0 -
How Much Cash Does Kiniksa Pharmaceuticals Have?
Cash and short term investments quarterly total is $206.4M -
What Is Kiniksa Pharmaceuticals’s Book Value Per Share?
Book value per share is 6.23
Is Kiniksa Pharmaceuticals Cash Flow Positive?
-
What Is KNSA Cash Flow From Operations?
Cash flow from operations (TTM) is $13.3M -
What Is Kiniksa Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is $1.5M -
What Is Kiniksa Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$29.6M
Kiniksa Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
KNSA return on invested capital is 3.45% -
What Is Kiniksa Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is 2.94% -
What Is KNSA Return On Equity?
ROE is a measure of profitability and is 3.45%
Kiniksa Pharmaceuticals Earnings Date & Stock Price
-
What Is Kiniksa Pharmaceuticals's Stock Price Today?
A single share of KNSA can be purchased today for 19.99 -
What Is Kiniksa Pharmaceuticals’s Stock Symbol?
Kiniksa Pharmaceuticals trades on the nasdaq under the ticker symbol: KNSA -
When Is Kiniksa Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Kiniksa Pharmaceuticals is scheduled on May 2, 2024 -
When Is KNSA's next ex-dividend date?
Kiniksa Pharmaceuticals's next ex-dividend date is June 17, 2020 -
How To Buy Kiniksa Pharmaceuticals Stock?
You can buy Kiniksa Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Kiniksa Pharmaceuticals Competitors
-
Who Are Kiniksa Pharmaceuticals's Competitors?
Below is a list of companies who compete with Kiniksa Pharmaceuticals or are related in some way:
Kiniksa Pharmaceuticals Dividend Yield
Data Unavailable
Kiniksa Pharmaceuticals Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 483.33% | 488.89% |
Revenue: | 34.76% | 15.39% |
Analyst Recommendations
Buy Recommendations: | 3 |
---|---|
Hold Recommendations: | 0 |
Sell Recommendations: | 0 |
Price Target: | 27.80 |
Upside from Last Price: | 39.07% |